Status:
WITHDRAWN
VALIDATE: Factor VIII Trending for MS Relapse
Lead Sponsor:
St. Joseph's Hospital and Medical Center, Phoenix
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Brief Summary
Multiple sclerosis (MS) patients hospitalized with an acute motor or visual relapse will be consented. Factor VIII-related labs will be systematically drawn for six months. During this time, patients ...
Detailed Description
The identification of blood tests that detect patients having Multiple Sclerosis (MS) relapses in real time could lead to a new era of MS relapse treatment. Accidental, anecdotal clinical observations...
Eligibility Criteria
Inclusion
- Adult patients aged 18-65 with an established diagnosis of relapsing remitting multiple sclerosis (RRMS);
- Patients with RRMS hospitalized at St. Joseph's Hospital and Medical Center in Phoenix, Arizona for an acute relapse affecting strength or vision;
- Patients may or may not be on disease modifying treatment;
- Entry EDSS score up to 7.0.
Exclusion
- Patients unable to have an MRI;
- Patients taking any heparin products, warfarin (Coumadin), apixiban (Eliquis), dabigatran (Pradaxa), or rivaroxaban (Xarelto);
- If stroke, tumor or other non-MS related cause is identified as the source of the patient's neurological issues.
Key Trial Info
Start Date :
August 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04082468
Start Date
August 13 2019
End Date
March 1 2022
Last Update
September 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barrow Neurological Institute
Phoenix, Arizona, United States, 85013